Login     Register  
    Home   |   Search   |   Director's Bio   |   About/Contact Us   |   Disclaimer  
BioEndeavor - Engaged Thinking  
 Home
 About BioEndeavor
 Engaged Thinking
 Engaged Thinking Blog
 Engaged Innovation Case Studies
 Engaged Thinking Academy
 Resources
 Engaged Innovation Directory
 Capacity Development
Neglected Tropical Diseases 
Non-Communicable Diseases 

Drug Discovery 
Preclinical 
Clinical 
Healthcare 
 Add Organization 


Drug Discovery
Abbott-DNDi Partnership to Boost Innovation for NTDsGo Back  
Organization URL

Organization:
Abbott-DNDi Partnership to Boost Innovation for NTDs

Year Established: 2009

Profile:
Since 2009, Abbott has provided compounds for DNDi to screen for activity against neglected diseases. Expanding on this relationship, Abbott is now providing DNDi access to research and development expertise of Abbott scientists, selected classes of molecules and accompanying data generated by Abbott that are crucial for the development of effective and accessible new treatments for neglected diseases.
Both DNDi and Abbott share their unique scientific expertise and resources to advance the development of drugs adapted to patient needs.
DNDi gains access to Abbott compounds, data and information to accelerate drug development.
Non-exclusive licensing structure for relevant IP in the neglected diseases field provides flexibility, thus expanding the potential of drug development.
Any resulting products will be provided in endemic countries at the lowest sustainable price to expand patient access.


Target Sector:
Drug Discovery

Typology of Knowledge Network:
Scientific Community

Knowledge Type / Focus:
Data
Biological Materials

Participant Type:
Non-Profit
Private Sector

Objective / Knowledge Governance:
Cooperative Research/Product Development

IP Management:
Sharing compounds and scientific and regulatory expertise with the Drugs for Neglected Diseases initiative (DNDi) to advance research on new treatments for NTDs. Partnering with DNDi to advance a preclinical development program evaluating the use of flubendazole for the treatment of lymphatic filiariasis (elephantiasis) and river blindness.


2010-2017 BioEndeavor.Net
Privacy and Security Statement Disclaimer Adding Directory Profiles